0.009).
Stepwise logistic regression analysis demonstrated the following factors to be associated with bacteriological eradication: absence of Pseudomonas aeruginosa (P < 0.01), higher weight (P < 0.01), a low APACHE IH score (P = 0.03), and treatment with ciprofloxacin (P = 0.04). When P. aeruginosa was recovered from initial respiratory tract cultures, failure to achieve bacteriological eradication and development of resistance during therapy were common in both treatment groups (67 and 33% for ciprofloxacin and 59 and 53% for imipenem, respectively). Seizures were observed more frequently with imipenem than with ciprofloxacin (6 versus 1%; P = 0.028). These results demonstrate that in patients with severe pneumonia, monotherapy with ciprofloxacin is at least equivalent to monotherapy with imipenem in terms of bacteriological eradication and clinical response. For both treatment groups, the presence of P. aeruginosa had a negative impact on treatment success. Seizures were more common with imipenem than with ciprofloxacin. Monotherapy for severe pneumonia is a safe and elfective initial strategy but may need to be modified if P. aeruginosa is suspected or recovered from patients.
Despite improvements in antimicrobial chemotherapy and supportive care, bacterial pneumonia, whether nosocomial or community acquired, remains an infection with substantial mortality. Nosocomial pneumonia accounts for about 15% of all hospital-acquired infections (20) and is the most common nosocomial infection among patients cared for in intensive care units (10) . In several recent reviews, mortality due to nosocomial pneumonia has been estimated to be 30 to 70% (6, 11, 12, 26) . However, most prospective antimicrobial clinical trials have been conducted in patient populations with mortality rates ranging from 4 to 33% (23, 28, 29, 31) . Severe cases of community-acquired pneumonia usually necessitate hospitalization and have been associated with a mortality rate as high as 21%, even among patients without obvious preexisting immune deficits (37, 47) .
A key component of the treatment for severe bacterial pneumonia is administration of an appropriate parenteral antibacterial regimen. The initial choice of agents is typically empiric, since the results of sputum and blood cultures are usually not available when therapy is started. The clinical diagnosis of pneumonia based upon conventional criteria only (i.e., fever, leukocytosis, new infiltrates on chest roentgenogram, and purulent sputum) may be inaccurate (2, 7, 12, 14, 44, 53) . Moreover, results obtained by culturing sputum aspirated from the airways of endotracheally intubated, mechanically ventilated patients may lack specificity compared with results obtained by more invasive means of sampling bronchial secretions (2, 12, 42, 45, 46) . In addition, pneumonia in mechanically ventilated patients is often polymicrobial (18) . For example, Fagon et al. found that multiple organisms were isolated from 40% of study patients (12) . Consequently, broad-spectrum antimicrobial coverage is generally recommended for the empirical or initial treatment of severe bacterial pneumonia (18) . Imipenem and ciprofloxacin are two broad-spectrum antimicrobial agents belonging to different chemical classes which have been evaluated as single agents for the treatment of pneumonia (19, 21, 23, 27, 38-40, 43, 49, 50) . Imipenem is a carbapenem antibiotic which possesses excellent in vitro activity against a wide range of pathogens implicated in the etiology of severe pneumonia, including methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, members of the family Enterobacteriaceae, and Haemophilus influenzae (34) . This drug also manifests good in vitro activity against Pseudomonas aeruginosa (34) . Ciprofloxacin is a fluorinated quinolone antimicrobial agent which demonstrates excellent in vitro activity against H. influenzae, members of the family Enterobacteriaceae, including Enterobacter cloacae, methicillinsusceptible S. aureus, and P. aeruginosa, and moderate activity against S. pneumoniae (51, 52 antibiotics, reaches levels in bronchial secretions above those in serum (5) , a property that might enhance its therapeutic efficacy in the treatment of pneumonia.
Intravenous (i.v.) ciprofloxacin is indicated for the treatment of mild-to-moderate lower respiratory tract infections at a dosage of 400 mg every 12 h. Our study was designed to assess treatment of patients with severe nosocomial or communityacquired pneumonia based on stringent entry criteria. In patients with severe pneumonia, because of the severity of the illness or the possible presence of pulmonary pathogens that may be only moderately susceptible to ciprofloxacin, administration of a higher dose might be warranted (38) . Therefore, the goal of the present study was to compare the efficacy and safety of ciprofloxacin (400 mg every 8 h) with those of imipenem (1,000 mg every 8 h), an antibiotic frequently used in the treatment of patients hospitalized with severe pneumonia (39) .
Previous clinical trials conducted to assess the efficacy of antibiotics for the treatment of pneumonia have been difficult to evaluate. Flaws of these studies have included lack of a double-blind design, exclusion of patients with underlying conditions associated with higher mortality, small sample sizes, and absence of intent-to-treat analyses (15-17, 27, 39-41, 43, 44) . Other trials allowed inclusion of patients with a variety of lower respiratory tract infections and therefore did not enroll a clearly defined patient population (15, 17, 21, 23, 37, 41, 43, 48, 49) . In the present study, we sought to avoid these criticisms and, accordingly, enrolled a relatively homogeneous population in which severity of illness measured by objective indices of respiratory dysfunction served as the entry criterion. The study was conducted and analyzed under fully blind conditions.
(This work was presented in part at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., 17 to 20 October 1993.) MATERLILS AND METHODS Study design. This was a multicenter, double-blind, randomized trial comparing i.v. ciprofloxacin with i.v. imipenem for the treatment of patients hospitalized (usually in intensive care units) with severe pneumonia. Twenty medical centers in the United States participated in the study and enrolled patients from May 1990 through July 1992. The study was approved by the institutional review board at each participating center. Informed consent was obtained from each patient (or an appropriate third party).
The objective of the study was to compare ciprofloxacin with imipenem for the treatment of severe pneumonia, with therapeutic equivalence being defined as a difference in bacteriological eradication rates of less than 10 percentage points (10%). The sample size objective to test this hypothesis for efficacy was 100 evaluable patients in each treatment group.
With a computer-generated code, patients were randomized to receive either i.v. imipenem-cilastatin or i.v. ciprofloxacin. Prior to randomization, patients were stratified on the basis of whether pneumonia was nosocomial or community acquired. Nosocomial pneumonia was defined as pneumonia developing after 48 or more h of hospitalization for another problem. All other cases of pneumonia, including those acquired in nursing homes, were considered community acquired.
Patient selection. The study inclusion criteria were as follows: 218 years of age; compromised respiratory function requiring a fractional inspired oxygen concentration of .0.35 to maintain an arterial oxygen tension of .60 mm Hg or being on mechanical ventilation at any oxygen concentration; at least 548 FINK ET AL. one symptom of bronchopulmonary infection (dyspnea; fever, hypothermia, or rigors; increase or new onset of cough; pleuritic chest pain; increase in sputum production or purulent sputum); new pulmonary infiltrate on chest roentgenogram thought to be due to infection; sputum Gram stain showing >25 polymorphonuclear neutrophils and <10 squamous cells and potentially pathogenic bacteria. The study exclusion criteria were as follows: allergy to a fluoroquinolone or ,B-lactam; pregnancy or nursing mother status; concurrent treatment with antimicrobial agents with activity spectra similar to those of the study drugs; absolute neutrophil count of .1,000 cells per mm3; prior antimicrobial treatment of the study infection for more than 24 h unless a persistent positive culture is documented; treatment with an investigational drug within 30 days prior to study enrollment or previous enrollment in this study. These criteria were designed to selectively enroll critically ill patients with pneumonia caused by identifiable pathogens.
Treatment. A high-dosage regimen of imipenem-cilastatin
(1,000 mg every 8 h) and ciprofloxacin (400 mg every 8 h) was designed for the treatment of susceptible pathogens. A lowerdosage schedule of the study agents (400 mg/12 h for ciprofloxacin and 500 mg/6 h for imipenem) was designed for the treatment of highly susceptible pathogens (imipenem dosing was based on package insert information). All patients were to be started on the high-dosage schedule. However, once susceptibility data were available, patients could be changed to the lower-dosage schedule at the discretion of the principal investigator at each center. Only a single change in the schedule (i.e., from the high to the lower dosage) was permitted by the protocol. Both schedules allowed for adjustment of the study medication dose for patients with renal impairment. This was performed by the study pharmacist (unblinded) on the basis of estimated creatinine clearance.
The study antibiotics were diluted by the research pharmacist to a volume of at least 150 ml with normal saline or a 5% dextrose solution. The study drug was infused i.v. over a period of 40 to 60 min.
Administration of antifungal agents, antiviral agents, topical antimicrobial agents, and oral vancomycin was permitted by the protocol. If aspiration was suspected as the etiology of pneumonia or if the sputum Gram stain suggested the presence of anaerobic bacteria, then administration of metronidazole was permitted for those patients randomized to ciprofloxacin treatment. Patients randomized to imipenem received a placebo infusion to maintain the blind condition. Use of i.v. vancomycin was permitted at the investigator's discretion for patients in both treatment groups with sputum cultures showing mixed gram-positive and gram-negative organisms or in patients with gram-positive bacteremia. If i.v. vancomycin was utilized, then the bacteriologic response to the study drug of any gram-positive organisms was excluded from efficacy analyses. The administration of other systemically active antimicrobial chemotherapy was prohibited by the protocol.
Bacteriological procedures. Appropriate cultures for isolation, identification, and susceptibility testing of organisms thought to be involved in the infectious process were obtained no more than 48 h prior to initiation of treatment. Sputum was the primary sample used for bacteriological documentation of pneumonia, although blood cultures were also obtained to document bacteremia. Susceptibility of bacterial isolates to the study drugs was determined by standard methods, and the results were assessed in accordance with published guidelines of the National Committee for Clinical Laboratory Standards (32, 33) . Routine cultures for Legionella pneumophila were not required by the protocol.
Evaluations for efficacy and safety. Patients were considered evaluable for both bacteriological and clinical responses if they met inclusion criteria, had at least one pretreatment pathogenic organism susceptible to both of the study drugs, and satisfied other evaluability criteria. The primary measure of study drug efficacy was bacteriological response at the end of therapy, which was defined as the time between days 3 and 7 posttherapy to allow for elimination of any residual antimicrobial drug which might prevent detection of persisting pathogenic bacteria. Bacteriological responses were classified as eradication (elimination of pretherapy organisms), presumed eradication (no material available for culture), persistence (continued isolation of the causative organisms), superinfection (acquisition of a new pathogen requiring treatment during study therapy), and indeterminate (bacteriological response to the study drug was not evaluable) (4, 8) .
Clinical response to therapy was a major secondary endpoint of the trial. Clinical response at 3 to 7 days after completion of therapy was assessed by each principal investigator. Clinical responses were classified as resolution (disappearance of signs and symptoms related to the infection), failure (insufficient lessening of the signs and symptoms of infection such that additional therapy was necessary), and indeterminate (no evaluation possible) (4, 8) . If during therapy the infection was improving but a patient died as a result of another disease process or study treatment of a patient was prematurely discontinued because of an adverse event, then the clinical response was considered improvement. If the infection was not improving or was thought to have contributed to the patient's demise, then the clinical response was graded as failure.
All adverse clinical events or laboratory abnormalities occurring during treatment or within 7 days of discontinuation of study medication were recorded and assessed by the principal investigator with regard to the relationship to the study drug and the severity of the event. Theophylline concentrations in serum were routinely monitored in patients receiving concomitant theophylline. Patient survival was recorded during therapy and for 30 days following drug discontinuation.
Premature termination of treatment. Any patient who received the study drug for less than 5 full days of treatment was not considered in the efficacy-evaluable analyses unless there was clear evidence of therapeutic failure. If the patient did not respond clinically or if a superinfection developed, treatment with the study drug was discontinued and other appropriate therapy was instituted. Patients dying within the first 48 h of therapy were classified as indeterminate, not as treatment failures, and were included in the analyses performed on the intent-to-treat population. These decisions were made before unblinding of the study. Statistical analyses. Results were analyzed to determine the comparative efficacy and safety of the two study drugs. Primary efficacy analyses were performed on only those cases meeting predetermined criteria for evaluability (efficacy-evaluable population). In addition, the same analyses for efficacy and all safety analyses were performed on the intent-to-treat population. All patients who received at least one dose of the study drug were included in the intent-to-treat population. No interim analysis was performed, and all data were processed by Miles Inc. All major variables were defined explicitly in the protocol, and no changes in the data base were made subsequent to breaking of the treatment allocation code.
The primary efficacy variable was bacteriological response at 3 to 7 days posttherapy. Clinical response at the same time point was considered a secondary outcome variable. For these two variables, 95% confidence intervals (CI) were constructed for the differences in eradication rates or resolution rates VOL. 38, 1994 between the two treatment groups, respectively. A CI that did not include -10% would indicate treatment equivalence; a lower limit greater than 0% would indicate ciprofloxacin superiority. Indeterminate responses were not included in the calculation of either eradication rates or resolution rates.
Overall tests of baseline comparability between the two treatment groups were conducted for several categorical variables by using the Cochran-Mantel-Haenszel test to adjust for the multicenter nature of the trial. Cochran-Mantel-Haenszel tests were also used for the efficacy variables. A Mantel-Haenszel weighting scheme was used to compute the CI (30). This method requires at least one evaluable patient per treatment group per center, resulting in the exclusion of five centers from the primary analyses; this decision was made prior to breaking of the treatment allocation code. To determine whether bacteriological and clinical response results were poolable across centers, a treatment-by-center interaction test was performed by the method of Zelen (54) .
Logistic regression was used to determine whether the treatment group or any clinical factor was a significant predictor of bacteriological and clinical responses. First, each variable that potentially affected eradication or resolution rates was included in logistic regression models to assess the ability of that variable to predict outcome (univariate model). Then, a stepwise logistic regression procedure was used to identify the best combination of variables by utilizing those variables that were significant predictors of outcome in the univariate model. Finally, treatment group was added to the best model selected by this stepwise procedure to determine whether it had significant explanatory value.
RESULTS
Patient characteristics. Twenty centers contributed to the study, enrolling 405 patients (205 in the ciprofloxacin treatment group and 200 in the imipenem treatment group). Three patients never received study medication after being randomized; the other 402 patients received either ciprofloxacin (n = 202) or imipenem (n = 200), and these patients constituted the intent-to-treat population. One patient was randomized to the imipenem treatment group but actually received ciprofloxacin; this patient was analyzed as part of the ciprofloxacin treatment group.
Of the 402 patients in the intent-to-treat population, 205 (98 in the ciprofloxacin treatment group and 107 in the imipenem treatment group) met the predetermined criteria for the efficacy-evaluable population. The reasons for excluding patients from the primary efficacy analyses are shown in Table 1 . All determinations of evaluability were made prior to unblinding.
Overall, the ciprofloxacin and imipenem treatment groups were statistically comparable with respect to almost all demographic variables ( Table 2 ). This was true for both the efficacyevaluable and the intent-to-treat populations. At the time of enrollment, both treatment groups were similar with respect to severity of illness, as quantitated by APACHE II scores (23a), and degree of pulmonary dysfunction, as estimated by the arterial oxygen tension/fractional inspired oxygen concentration ratio and the alveolar-arterial oxygen tension gradient. Approximately four-fifths of both the efficacy-evaluable and intent-to-treat patients were classified as having nosocomial pneumonia and were being mechanically ventilated at the time of randomization.
Treatment. Among patients considered to be efficacy evaluable, the mean durations of treatment were 10.5 days in the ciprofloxacin group and 10.1 days in the imipenem group (P = 0.703). Eighty percent of ciprofloxacin-treated patients and 82% of imipenem-treated patients in the intent-to-treat population received the high-dosage regimen throughout the entire study. In the efficacy-evaluable population, 76% of ciprofloxacin-treated and 78% of imipenem-treated patients received the high-dosage regimen throughout the study. The mean durations of the high-dosage regimen in the ciprofloxacin and imipenem treatment groups were 9.5 and 8.8 days, respectively (P = 0.809). Among the patients considered for the intent-to-treat analyses, the mean durations of treatment were approximately 1 day shorter for both treatment groups.
In the efficacy-evaluable population, 58 (59.2%) of the patients in the ciprofloxacin treatment group and 71 (66.4%) of the patients in the imipenem treatment group had been treated with nonstudy antimicrobial agents prior to enrollment. Concomitant antimicrobial agents were employed by 42 (43%) ciprofloxacin-treated patients and 50 (47%) imipenem-treated patients in the efficacy-evaluable population. The concomitant antibacterial agents permitted by the protocol included vancomycin (27 patients) and metronidazole (11 patients) in the ciprofloxacin treatment group. In the imipenem treatment group, 31 patients received vancomycin and 16 received a placebo for metronidazole to maintain the blind condition. Both gram-positive and gram-negative organisms were isolated from all of the efficacy-evaluable patients who received vancomycin (11 in the ciprofloxacin treatment group and 8 in the imipenem treatment group). A few patients in both treatment groups concomitantly received antibiotics excluded by the protocol. These patients were evaluated on an individual basis prior to breaking of the treatment allocation code and were considered valid for the analyses of efficacy if at least one pretreatment respiratory pathogen was not susceptible to the concomitantly administered antibiotic (4, 8) . stepwise procedure included all three variables which were predictive in the univariate analyses. When treatment group 127 (62.9) 127 (63.5) was added to this model, ciprofloxacin therapy resulted in a bacteriological eradication rate significantly superior (P = t the time of randomization into the 0.039) to that of imipenem therapy (Table 4 ). treatment groups were statistically Clinical resolution rates in the efficacy-evaluable population also were analyzed by logistic regression to determine whether on gradient. ciprofloxacin was statistically superior to imipenem, even when actional inspired oxygen concentra-other potentially confounding factors were simultaneously considered. In the univariate analyses, the requirement for atment group had nonpulmonary mechanical ventilation, a higher leukocyte count, a higher APACHE II score, and presence of P. aeruginosa at entry all wntensive care unit were found to have a statistically significant adverse impact on the resolution rate. Since leukocyte count is a component of the APACHE II score, only the APACHE II score was Voi,.. 38, 1994 (Table 4) . Thus, even after adjustment for confounding variables, clinical outcome in the ciprofloxacin treatment group was statistically superior to that in the imipenem treatment group (P = 0.016). Pathogenic organisms. The spectrum of organisms isolated from the respiratory tract at study entry was similar in the two treatment groups for both the efficacy-evaluable and the intent-to-treat populations (data not shown). The most common isolates encountered in the intent-to-treat population were P. aeruginosa (n = 91), H. influenzae (n = 72), methicil-lin-susceptible S. aureus (n = 60), Klebsiella pneumoniae (n = 46), and Escherichia coli (n = 30). The frequency of E. cloacae and K pneumoniae isolates was greater in the imipenem treatment group than in the ciprofloxacin treatment group (16 versus 7 for E. cloacae and 29 versus 17 for K pneumoniae, respectively); these differences were not statistically significant. In the intent-to-treat population, 94.1% of the organisms isolated at study entry were susceptible in both the ciprofloxacin and imipenem treatment groups, and in the efficacyevaluable population, 98.6 and 96.5% of the organisms isolated from ciprofloxacin-and imipenem-treated patients, respectively, were susceptible at entry (32, 33) .
The bacteriological eradication rates for each causative organism at the respiratory site are shown in Table 5 . Overall, the ciprofloxacin treatment group showed a higher rate of pathogen eradication than did the imipenem treatment group for both the efficacy-evaluable population (76 versus 68%, respectively) and the intent-to-treat population (73 versus 66%, respectively). This was primarily due to the statistically superior ability of ciprofloxacin to eradicate members of the family Enterobacteriaceae (41 of 44 [93%] for ciprofloxacin versus 45 of 68 [66%] for imipenem; P = 0.001) in the efficacy-evaluable population. The two antimicrobial agents were comparable with regard to eradication of S. aureus, H. influenzae, S. pneumoniae, and P. aeruginosa, for both the efficacy-evaluable and the intent-to-treat populations. In both treatment groups, bacteriological failure was common when P. aeruginosa was a pretreatment respiratory pathogen. In the efficacy-evaluable population, bacteriological eradication of P. aeruginosa was greater, but not significantly so, in the imipenem group than in the ciprofloxacin group (11 [41%] versus 11 [33%], respectively; P = 0.559). Development of resistance. The development of bacteriological resistance by organisms that were initially susceptible to the study antimicrobial agents is shown in Table 6 . In the intent-to-treat population, both treatment groups exhibited similar rates of development of resistance: 9% for the ciprofloxacin treatment group and 11% for the imipenem treatment group. There were 23 isolates from 20 ciprofloxacin-treated patients and 27 isolates from 27 imipenem-treated patients that developed resistance during the course of the study in the intent-to-treat population. P. aeruginosa was the predominant pathogen developing resistance to ciprofloxacin or imipenem in both the intent-to-treat and efficacy-evaluable patients. For this organism, 13 (28%) of 47 isolates in the ciprofloxacin treatment group and 22 (50%) of 44 isolates in the imipenem treatment group developed resistance in the intent-to-treat population. Resistance to P. aeruginosa did not develop before day 3 of treatment, but by day 7 of therapy, 6 (of 13) isolates in the ciprofloxacin treatment group and 13 (of 22) isolates in the imipenem treatment group had become resistant.
Superinfection. Superinfection was caused by 21 isolates in 18 ciprofloxacin-treated patients and by 37 isolates in 30 imipenem-treated patients in the efficacy-evaluable population. In the intent-to-treat population, superinfection was caused by 32 isolates in 28 ciprofloxacin-treated patients and caused by 53 isolates in 41 imipenem-treated patients. Although certain species of superinfecting organisms seemed to be study drug specific, P. aeruginosa, K pneumoniae, and Xanthomonas maltophilia were the primary pathogens causing superinfection in the efficacy-evaluable population ( Table 6 ).
Premature discontinuation from study treatment. Treatment with the study drug was discontinued prematurely for 192 of 402 patients; of these, 96 were in the ciprofloxacin treatment group and 96 were in the imipenem treatment group. Reasons for premature drug discontinuation were as follows (the percentages of all patients in the ciprofloxacin and imipenem treatment groups, respectively, are in parentheses): failure to respond clinically (12 and 20% [P = 0.032]), violation of inclusion or exclusion criteria (14 and 7% [P = 0.020]), death (5 and 3% [P = 0.332]), adverse reaction (3 and 5% [P = 0.575]), and miscellaneous factors (12 and 14% [P = 0.695]).
Adverse events. Adverse events were reported for 132 (65%) of 202 patients in the ciprofloxacin treatment group and for 148 (74%) of 200 patients in the imipenem treatment group, a difference that was not statistically significant (P = 0.059). However, seizures occurred in only 3 (1%) of 202 patients in the ciprofloxacin treatment group, compared with 11 (6%) of 200 patients in the imipenem treatment group (P = 0.028). In two ciprofloxacin-treated patients, seizures occurred more than a week after the study drug was discontinued. In contrast, all seizures in the imipenem treatment group occurred during therapy with imipenem. Myocardial infarction occurred in 2% VOL. 38, 1994 of imipenem patients but not at all in the ciprofloxacin treatment group (P = 0.030). Other adverse events occurred with similar frequencies in both treatment groups. Changes in laboratory values of possible clinical significance that occurred with significantly different frequencies in the two treatment groups included hematocrit decreases (55% of ciprofloxacin-treated patients versus 65% of imipenem-treated patients), uric acid decreases (36 versus 49%), and blood urea nitrogen elevations (24 versus 13%). In addition, 38 and 39% of the ciprofloxacinand imipenem-treated patients, respectively, who were receiving concomitant theophylline had increases in levels of theophylline in serum of -25% from the baseline at some time during the study. However, toxicity was not ascribed to theophylline by any investigator.
Mortality. There were 81 (20%) deaths in the intent-to-treat population while patients received the study drug or within the 30-day posttherapy period.
During the first 48 h after study entry, 11 patients (4 imipenemand 7 ciprofloxacin-treated patients) died. P. aeruginosa was isolated from one of the ciprofloxacin-treated patients and one of the imipenem-treated patients who died within the first 48 h of therapy. P. aeruginosa was isolated on initial culture from 19 (23%) of the 81 patients who died, and only 2 (3%) of these patients died within the first 48 h of the study.
Of the 81 deaths that occurred, 43 were in the ciprofloxacin treatment group and 38 were in the imipenem treatment group (P = 0.619). Eighteen of the 43 deaths in the ciprofloxacin treatment group were attributed to the patients' underlying disease(s), 23 were attributed to bacterial infection, and 2 were considered indeterminate. In the imipenem treatment group, 21 deaths were attributed to an accompanying disease(s), 15 were attributed to bacterial infection, and 2 were considered indeterminate. As stated previously, these assignments were made by the investigators prior to unblinding of the study. The difference in the number of deaths attributed to bacterial infection in the ciprofloxacin versus the imipenem treatment group was not statistically significant (P = 0.199). DISCUSSION Parenterally administered antimicrobial agents remain the cornerstone of therapy for severe pneumonia. Although numerous clinical studies have compared various antimicrobial regimens for the treatment of pneumonia, the ability to draw meaningful conclusions regarding the relative efficacy or safety of the agents being evaluated has often been compromised by aspects of trial design or the way results were analyzed and reported. Previous trials often excluded critically ill patients, especially those requiring mechanical ventilation or with severe renal or hepatic dysfunction (16, 17, 43) . Most previous trials have employed nonblind study designs (15, 16, 23, 27, 48, 49) , lacked an intent-to-treat analysis (16, 27) , suffered from small patient sample sizes (39) (40) (41) 44) , or enrolled patients with other infections in addition to pneumonia (21, 23, 27, 48, 49) . This is the first large, randomized, double-blind comparative antimicrobial clinical trial utilizing a rigorous prospective study design with patients with severe pneumonia of which we are aware. Among the strengths of this study were the use of double-blind treatment assignment, analysis of predetermined endpoints before unblinding of the treatment allocation code, and enrollment of patients on the basis of severity of illness. This yielded a large, well-characterized, relatively homogeneous population of seriously ill patients, as evidenced by the large proportion requiring mechanical ventilation and the high initial APACHE II scores. Efficacy analyses of the data were performed for both the efficacy-evaluable and the intent-totreat populations of patients.
The primary endpoint of this study was eradication of the pretreatment respiratory pathogen(s). Although the difference is not quite statistically significant by univariate analysis, treatment with ciprofloxacin resulted in a 10% higher bacteriological eradication rate than that observed in the imipenemtreated patients. The difference in bacteriological outcome was due mainly to the significantly higher eradication rate among members of the family Enterobacteriaceae in the ciprofloxacin treatment group. By using multivariate analysis to control for the presence of P. aeruginosa at initiation of therapy, patient 554 FINK ET AL.
weight, and APACHE II score, ciprofloxacin therapy resulted in a bacteriological eradication rate significantly superior to that achieved with imipenem.
In this large, multicenter study, we have also shown that monotherapy with i.v. ciprofloxacin was superior to imipenem with respect to clinical efficacy in the efficacy-evaluable patient population. Furthermore, even after adjustment for potentially confounding factors highly associated with clinical failures, such as ventilator dependence, APACHE II score, and the presence of P. aeruginosa in the pretreatment sputum culture, ciprofloxacin treatment was significantly superior to imipenem in clinical efficacy, according to stepwise logistic regression analysis. In the intent-to-treat analysis, the difference in efficacy between the two treatment regimens did not quite reach significance.
A major clinical question is whether the use of a single antibiotic is sufficient for treatment of severe bacterial pneumonia in seriously ill patients, especially if the infection is with a nosocomially acquired gram-negative bacillus. The results presented here suggest that monotherapy is adequate for treatment of most cases of serious community-and hospitalacquired pneumonia, even in ventilator-dependent patients, unless the causative organism is P. aeruginosa. If cases with P. aeruginosa are excluded, the bacteriological eradication rates for the ciprofloxacin and imipenem treatment groups are 86 and 66%, respectively. Although some patients did receive concomitant antimicrobial agents, these agents did not generally overlap the spectrum of either study drug.
The importance of P. aeruginosa as a respiratory pathogen associated with severe illness and poor outcome is underscored by our stepwise logistic regression analysis, which indicates that the risk of clinical failure with either study drug was approximately double when this organism was cultured prior to institution of therapy. Of the P. aeruginosa strains which were susceptible to ciprofloxacin and imipenem prior to therapy, 33 and 53%, respectively, developed resistance during the trial in the efficacy-evaluable population. Even combination therapy with two appropriate antipseudomonal antibiotics may not result in clinical cure, lead to eradication of the organism, or prevent development of resistance (3, 36) . In our study, for two-thirds of patients for whom study drug therapy failed, the failure was still evident at the 14to 28-day posttherapy evaluation, despite the use of subsequent nonstudy antimicrobial agents. Nevertheless, in view of the overall increased likelihood of treatment failure or development of resistance reported in the literature and confirmed by this study, monotherapy with either imipenem or ciprofloxacin cannot be recommended for the treatment of pneumonia when P. aeruginosa is isolated. Although there are data that support the use of more than one antipseudomonal agent for the treatment of P. aeruginosa bacteremia (22) , it is noteworthy that in no patient in this study with P. aeruginosa did resistance to either treatment regimen develop earlier than 3 days after initiation of treatment. Furthermore, the proportion of early deaths associated with pretherapy isolation of P. aeruginosa was not different from that associated with other organisms. Therefore, when a patient develops severe pneumonia, initial empiric antibiotic therapy with a single potent, broad-spectrum agent is reasonable until culture results are obtained. If P. aeruginosa is isolated, then the use of combination therapy appears to be prudent to avoid the emergence of resistance, although routine use of combination antibiotics for severe pneumonia may increase the risk of toxicity or superinfection (24) .
There are some limits to this study. Recent data suggest that the clinical criteria used to diagnose pneumonia lack specificity (2, 13, 42, 45, 46) . Although strict diagnostic criteria were employed, newer invasive diagnostic methods, such as use of a protected specimen brush or bronchoalveolar lavage, were not routinely employed in this study. However, our entry criteria were those which most clinicians would still employ to make a diagnosis of pneumonia and are consistent with recently published guidelines for the conduct of clinical studies for anti-infective agents (4, 8) . While some invasive diagnostic procedures may eventually gain wider acceptance, they are not routinely used to make a bacteriological or clinical diagnosis in most institutions. Furthermore, few data that demonstrate a clear diagnostic or prognostic benefit for these procedures are available (9, 35) .
In addition, it must be emphasized that our study population was not necessarily representative of all patients with severe pneumonia. This was primarily because many of the investigators who participated in the study were intensivists or pulmonologists in charge of intensive care units. Nevertheless, the results described here are probably generalizable to most patients with severe pneumonia, especially those receiving mechanical ventilation.
The only two adverse events of statistical significance were seizures and myocardial infarction. Both ciprofloxacin and imipenem have been associated with central nervous system side effects, such as seizures (1, 25) . In the present study, seizures occurred significantly more frequently among patients treated with imipenem than among those treated with ciprofloxacin, despite an equal distribution of predisposing conditions. The occurrence of myocardial infarction, although not explainable, was limited to the imipenem treatment group.
In summary, this multicenter, prospective, randomized, blinded, controlled trial demonstrated that ciprofloxacin is superior to imipenem with respect to the clinical response of patients and equivalent to imipenem with respect to eradication of pulmonary pathogens in patients with severe pneumonia. The major risk factors for failure of bacteriological eradication were presence of P. aeruginosa, a low body weight, and a high APACHE II score. Risk factors for clinical failure with either regimen also included a high APACHE II score and the presence of P. aeruginosa in the pretreatment culture, as well as ventilator dependence. Antibiotic monotherapy can be used successfully to treat severe pneumonia; however, this study clearly demonstrates that additional strategies are necessary to treat pneumonia associated with P. aeruginosa, although initial monotherapy appears to be safe for 48 h, until culture results are obtained.
